CAPR Loss Alert: Lose Money on Your Capricor Therapeutics Investment? BFA Law Reminds Investors of the Ongoing Securities Fraud Class Action to Recover Losses
Plaintiff firm Bleicher Fonti & Auld LLP (BFA Law) is soliciting Capricor Therapeutics (NASDAQ: CAPR) investors for a securities fraud class action pending in the U.S. District Court for the Southern District of California, captioned Nkamga v. Capricor Therapeutics, Inc. et al., No.
Key figures
- Drug Name
- Deramiocel
- Court
- U.S. District Court for the Southern District of California
- Adcom vote
- 9-3 non-binding vote that evidence did not support Deramiocel efficacy
- Case number
- No. 26-cv-04385
- Stock drop pct jul27
- 64.5%
- Stock drop pct jul30
- 36%
- Lead plaintiff deadline
- September 28, 2026
- Stock price jul24 close
- 19.7
- Stock price jul27 close
- 7
- Stock price jul29 close
- 6.57
- Stock price jul30 close
- 4.19
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.